-
A new round of large-scale procurement of consumables! Can the "foreign monopoly" of Johnson & Johnson, Abbott and Medtronic be broken?
Time of Update: 2022-10-19
"It can be seen from the results that overseas enterprises in the centralized procurement of medical equipment consumables no longer occupy an advantage, and 'import substitution' is increasing its proportion; more and more domestic equipment companies are joining the electrophysiological track, some enterprises continue to break through core technologies, and large-scale collective procurement is launched.
-
The drastic changes in circulation have given birth to the "one-vote system", and the "two-vote system" has been canceled? National Health Insurance Administration: "Two-invoice system" plays an important role!
Time of Update: 2022-10-19
On October 12, the National Medical Security Administration issued a group of suggestions from deputies to the National People's Congress and a reply to the proposal of members of the National Commit
-
Recently, a large number of domestic and foreign pharmaceutical companies have opened the "fire sale mode"!
Time of Update: 2022-10-19
, Ltd. On September 30, Zima Gene issued an announcement that in order to reduce the company's management costs, the meeting deliberated and passed a proposal to cancel its wholly-owned subsidiary, Anhui Zima Gene Pharmaceutical Co.
-
The "unlimited cancer" therapy track is winding: Merck, Eli Lilly, Novartis lead, and the cornerstone comes later?
Time of Update: 2022-10-19
In March 2021, platinib was approved for the first time in China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had previously received platinum-containing chemotherapy with transfection rearrangement (RET) gene fusion, becoming the first highly selective RET inhibitor approved for marketing in China.
-
National Health Insurance Administration Releases Medical Insurance Management Efficiency Improvement Cases (Eighth Batch)
Time of Update: 2022-10-19
Innovation is the first driving force to lead development, and to promote the refined management of medical insurance, we must constantly adapt to the new environment, promote the application of new
-
China's first continuous manufacturing guide is coming, and the pharmaceutical industry will usher in major changes!
Time of Update: 2022-10-19
In order to encourage innovation and pharmaceutical modernization, help the implementation of the ICH Q13 guiding principles in China, and also guide enterprise research and development, unified eval
-
Chia Tai sky is open and hanging! 61 Class 1 new drugs and 7 blockbuster monoclonal antibody screens
Time of Update: 2022-10-19
Recently, the R&D pipeline of CP Tianqing Pharmaceutical welcomes new progress: class 1 new drug TQB2102 is declared for clinical for the first time, the introduction of heavy NASH new drugs, and cla
-
Hundreds of billions of market value pharmaceutical stocks "waist cut", TOP20 big shuffle!
Time of Update: 2022-10-19
Enwei Pharmaceutical officially landed on A-share on September 21, the company is mainly engaged in the research and development, production and sales of proprietary Chinese medicines and chemical drugs, focusing on gynecology, pediatrics, respiratory system and other fields, with 17 exclusive varieties including Jieer Yin lotion, Shanmai Spleen Oral Liquid, Danxiong Tongmai granules, etc.
-
Innovative therapies are favored, pharmaceutical companies are constantly "buying, buying and buying"
Time of Update: 2022-10-19
For example, on October 3, Alexion Pharmaceuticals, a subsidiary of AstraZeneca's rare disease business, announced the acquisition of LogicBio Therapeutics, a clinical-stage genetic company, for $68 million.
-
Update on medical insurance catalogue adjustment: expert review work concluded
Time of Update: 2022-10-19
The National Medical Insurance Administration previously said that the adjustment of the medical insurance drug catalogue is divided into enterprise declaration, formal review, expert review, negotiation and bidding.
-
Self-built M&A franchise alliance, pharmaceutical retail chain enterprises enter the "era of 10,000 stores"
Time of Update: 2022-10-19
A few days ago, four listed chain pharmacy enterprises (hereinafter referred to as the four major chain pharmacies) including Da Shenlin Pharmaceutical Group Co. , Ltd. (hereinafter referred to as Da
-
A large number of designated medical institutions have been exposed to the illegal use of medical insurance funds!
Time of Update: 2022-10-19
js?cdnversion='+~(-new Date()/36e5)]; In May this year, the National Medical Insurance Bureau issued the "Notice on the Unannounced Inspection of the Medical Security Fund in 2022" and said that in the second half of this year, the National Medical Insurance Bureau, the Ministry of Finance, the National Health Commission, and the State Administration of Traditional Chinese Medicine will jointly organize and carry out unannounced inspections of medical insurance funds, covering 31 provinces across the country.
-
Domestic production has grown, and imported drugs are no longer "dominating" the asthma category
Time of Update: 2022-10-19
The average unit price of TOP5 products is high In terms of drugs, in the first half of 2022, there were 32 anti-asthmatic drugs sold in the sample hospitals, and the top five were budesonide, compound budesonide formoterol, montelukast, terbutaline and compound fluticasone salmetarol, with a total sales of more than 751 million yuan, accounting for 54.
-
Anti-thrombotic "one brother" stop falling! Exclusive varieties soar 122%
Time of Update: 2022-10-19
The antithrombotic drug market is making a comeback! Recently, Simcere Pharmaceutical won the first imitation of edoxaban tosylate, and Kelun Pharmaceutical's sulda hepaparanox injection and Tianfang
-
Top20 announced! Yangtze River and China Resources Sanjiu lead the stomach medicine market
Time of Update: 2022-10-19
In the second half of this year, the good news of Class 1 new drugs of gastric medicine and traditional Chinese medicine continued: Tong Drop granules were declared for clinical trial in August, and
-
The national centralized procurement of proprietary Chinese medicines will accelerate the reshuffle of the industry and form a pattern of "the strong and the strong"
Time of Update: 2022-10-19
For example, on the evening of December 28, 2021, the company announced that it had signed a "strategic cooperation agreement" with Beijing Yingkerui to fully carry out R&D cooperation in proprietary Chinese medicines, and signed a technology transfer contract with its wholly-owned subsidiary Yingkerui (Tianjin) Innovative Pharmaceutical Research Co.
-
60% of pharmaceutical and biological companies in Shenzhen reported good news, and some companies recorded triple-digit growth
Time of Update: 2022-10-19
【Pharmaceutical Network Industry News】 Analysts said that the industry results of pharmaceutical biology in the third quarter are worth optimizing. For example, Ping An Securities analysis believes th
-
Registration application for additional information exceeded the time limit? NMPA: It can be extended!
Time of Update: 2022-10-19
3. For drug registration applications issued by the Drug Review Center of the State Food and Drug Administration from the date of this announcement to December 31, 2022, the time limit for supplementary information is extended to 160 working days.
-
The State Food and Drug Administration on the deferral of the payment of drug and medical device product registration fees
Time of Update: 2022-10-14
↵ According to the Announcement on Deferring the Payment of Some Administrative Fees Involving Enterprises and Individual Industrial and Commercial Households (Announcement [2022] No. 29 of the Minis
-
Under the accelerated innovation and transformation, a large number of pharmaceutical companies have entered the harvest period
Time of Update: 2022-10-14
By continuously increasing R&D efforts, Yiling Pharmaceutical has actively carried out new drug research and development in the fields of cardiovascular and cerebrovascular system diseases, diabetes, respiratory diseases, tumors, nervous system diseases, urinary system diseases and other clinical and major diseases, and some innovative achievements have also entered the harvest period.
